Terence Flynn

GLP-1 therapies are at a convergence moment with five drivers pushing the next phase of adoption: shift to oral medications, expanding access through Medicare, lower costs and broader insurance coverage, global expansion, and innovation beyond weight loss. This could lead to a $190 billion market by 2035 with a bull case of $240 billion, supported by low current penetration and significant growth runway.